haloperidol has been researched along with Emesis in 87 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0." | 9.41 | Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. ( Crawford, FM; Day, AG; Forrester, S; Hall, AK; Ruberto, AJ; Sivilotti, MLA, 2021) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 9.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "Haloperidol as an adjunctive therapy is superior to placebo for acute gastroparesis symptoms." | 9.24 | Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis. ( Cardenas-Turanzas, M; Chambers, KA; Chathampally, Y; Paniagua, L; Patel, S; Roldan, CJ, 2017) |
| "Haloperidol is used commonly for the control of nausea and vomiting (N/V) in palliative care patients, but there is very little evidence to support its use." | 9.14 | The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. ( Douglas, C; Gilshenan, K; Hardy, JR; O'Shea, A; Welch, L; White, C, 2010) |
| " This study compared ziprasidone with the conventional antipsychotic haloperidol in outpatients with stable schizophrenia." | 9.10 | A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. ( Bäuml, J; Hirsch, SR; Kissling, W; O'Connor, R; Power, A, 2002) |
| "Tropisetron is a novel antiserotoninergic drug with potent and specific activity against cancer chemotherapy-induced emesis." | 9.07 | Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. ( Bonadonna, G; Bregni, M; Di Nicola, M; Gianni, AM; Siena, S, 1991) |
| "The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer." | 9.06 | A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988) |
| "0 mg) of haloperidol with that of placebo for the relief of vomiting and nausea due to gastrointestinal disorders." | 9.04 | Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study. ( Nagel, JD; Robbins, EL, 1975) |
| "Sixty-two postoperative patients were admitted to a double-blind study to compare the therapeutic effectiveness of a single intramuscular injection of 1 mg of haloperidol with that of a placebo for the relief of vomiting and nausea following surgical procedures." | 9.04 | The use of haloperidol for treatment of postoperative nausea and vomiting--a double-blind placebo-controlled trial. ( Barton, MD; Cohen, PJ; Libonati, M, 1975) |
| "To evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients." | 8.91 | Haloperidol for the treatment of nausea and vomiting in palliative care patients. ( Dorman, S; Murray-Brown, F, 2015) |
| "The primary objective of the review was to evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients." | 8.85 | Haloperidol for the treatment of nausea and vomiting in palliative care patients. ( Dorman, S; Perkins, P, 2009) |
| "Haloperidol (HL) has successfully been used for nausea and abdominal pain in emergency departments (EDs)." | 8.02 | Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain. ( Jehangir, A; Malik, Z; Parkman, HP; Repanshek, ZD; Reznick-Lipina, K; Shahsavari, D; Weiner, M, 2021) |
| "A short-cut review was carried out to establish whether haloperidol is effective at treating the symptoms of cannabinoid hyperemesis syndrome (CHS)." | 7.88 | BET 1: Haloperidol in cannabinoid hyperemesis syndrome. ( Dida, J; Walji, N, 2018) |
| " From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i." | 7.70 | The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "Haloperidol (HP) has been shown to have analgesic & antiemetic properties." | 5.46 | Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department. ( Croft, B; Darracq, MA; Ramirez, R; Stalcup, P, 2017) |
| "We randomized cannabis users with active emesis to either haloperidol (with a nested randomization to either 0." | 5.41 | Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. ( Crawford, FM; Day, AG; Forrester, S; Hall, AK; Ruberto, AJ; Sivilotti, MLA, 2021) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 5.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "Haloperidol as an adjunctive therapy is superior to placebo for acute gastroparesis symptoms." | 5.24 | Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis. ( Cardenas-Turanzas, M; Chambers, KA; Chathampally, Y; Paniagua, L; Patel, S; Roldan, CJ, 2017) |
| "The topical gel known as "ABH gel," comprising lorazepam (Ativan(®)), diphenhydramine (Benadryl(®)), and haloperidol (Haldol(®)), is frequently used to treat nausea because of its perceived efficacy, relatively low cost, and ease of use in the home setting." | 5.19 | A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea. ( Coyne, PJ; Dodson, PW; Fletcher, DS; Parker, GG; Smith, TJ; Wan, W, 2014) |
| "Haloperidol is used commonly for the control of nausea and vomiting (N/V) in palliative care patients, but there is very little evidence to support its use." | 5.14 | The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. ( Douglas, C; Gilshenan, K; Hardy, JR; O'Shea, A; Welch, L; White, C, 2010) |
| " This study compared ziprasidone with the conventional antipsychotic haloperidol in outpatients with stable schizophrenia." | 5.10 | A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. ( Bäuml, J; Hirsch, SR; Kissling, W; O'Connor, R; Power, A, 2002) |
| "Tropisetron is a novel antiserotoninergic drug with potent and specific activity against cancer chemotherapy-induced emesis." | 5.07 | Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy. ( Bonadonna, G; Bregni, M; Di Nicola, M; Gianni, AM; Siena, S, 1991) |
| "The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer." | 5.06 | A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988) |
| "Sixty-four patients receiving cancer chemotherapy known to induce severe emesis entered a randomized double-blind study of the antiemetic efficacy of haloperidol (Haldol) and benzquinamide (Emetecon)." | 5.05 | Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide. ( Gagen, M; Neidhart, JA; Wilson, HE; Young, D, 1981) |
| "Metoclopramide is an effective antiemetic for cisplatin-induced vomiting when given in parenteral high-dose regimens but not oral low-dose regimens." | 5.05 | Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. ( Cariffe, P; Gala, KV; Grunberg, SM; Jamin, D; Johnson, K; Krailo, M; Lampenfeld, M; Strych, D, 1984) |
| "0 mg) of haloperidol with that of placebo for the relief of vomiting and nausea due to gastrointestinal disorders." | 5.04 | Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study. ( Nagel, JD; Robbins, EL, 1975) |
| "Sixty-two postoperative patients were admitted to a double-blind study to compare the therapeutic effectiveness of a single intramuscular injection of 1 mg of haloperidol with that of a placebo for the relief of vomiting and nausea following surgical procedures." | 5.04 | The use of haloperidol for treatment of postoperative nausea and vomiting--a double-blind placebo-controlled trial. ( Barton, MD; Cohen, PJ; Libonati, M, 1975) |
| "To evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients." | 4.91 | Haloperidol for the treatment of nausea and vomiting in palliative care patients. ( Dorman, S; Murray-Brown, F, 2015) |
| " In postoperative nausea and vomiting (PONV), two randomized controlled trials found treatment with haloperidol comparable to ondansetron." | 4.89 | Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. ( Bennett, MI; Blenkinsopp, A; McLean, SL, 2013) |
| "The primary objective of the review was to evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of nausea and vomiting in palliative care patients." | 4.85 | Haloperidol for the treatment of nausea and vomiting in palliative care patients. ( Dorman, S; Perkins, P, 2009) |
| "Haloperidol (HL) has successfully been used for nausea and abdominal pain in emergency departments (EDs)." | 4.02 | Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain. ( Jehangir, A; Malik, Z; Parkman, HP; Repanshek, ZD; Reznick-Lipina, K; Shahsavari, D; Weiner, M, 2021) |
| "A short-cut review was carried out to establish whether haloperidol is effective at treating the symptoms of cannabinoid hyperemesis syndrome (CHS)." | 3.88 | BET 1: Haloperidol in cannabinoid hyperemesis syndrome. ( Dida, J; Walji, N, 2018) |
| "Settings were postoperative nausea or vomiting (1,994 patients), gastroenterology (261), chemotherapy (189), and radiation therapy (24)." | 3.81 | Is low-dose haloperidol a useful antiemetic?: A meta-analysis of published and unpublished randomized trials. ( Büttner, M; Tramèr, MR; von Elm, E; Walder, B, 2004) |
| " From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i." | 3.70 | The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support. ( Aznar, E; Climent, MA; Guillem, V; Olmos, T; Palau, J; Ruiz, A; Soriano, V, 1998) |
| "A new benzamide, cis-N-(1-benzyl-2-methylpyrrolidin - 3 - yl) - 5 - chloro - 2 - methoxy - 4 - methylaminobenzamide (YM-09151-2) exhibited more potent and longer-lasting inhibitory effects on apomorphine-induced behaviours (stereotyped behaviour, emesis and hypothermia), and methamphetamine-induced stereotyped behaviour, conditioned avoidance response and open field behaviour, conditioned avoidance response and open field behaviour than either structurally similar benzamides (YM-0850 and sulpiride) or classical neuroleptics [chlorpromazine (CPZ) and haloperidol(HPD)]." | 3.66 | Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity. ( Maeno, H; Nishikori, K; Noshiro, O; Usuda, S, 1981) |
| "5 mg intravenous haloperidol in an effort to improve patient tolerance of cytotoxic chemotherapy and decrease nausea and vomiting." | 3.66 | Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy. ( Coates, A; Fox, RM; Friedlander, ML; Hedley, D; Kearsley, JH; Raghavan, D; Sims, K; Tattersall, MH, 1983) |
| " Compound 2e was much less active than haloperidol in antagonizing apomorphine-induced emesis in dogs, apomorphine-induced stereotypy in rats, and amphetamine-induced circling in lesioned rats." | 3.66 | Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 4. Central nervous system depressants. ( Allen, RC; Bauer, VJ; Cornfeldt, ML; Fielding, S; Geyer, HM; Kosley, RW; McFadden, AR; Shutske, GM; Wilker, JC, 1978) |
| " Ironically, chronic use of cannabis can result in paradoxical effects, including a condition known as cannabinoid hyperemesis syndrome." | 2.61 | Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting. ( Forest, CP; Smith, TN; Walsh, A, 2019) |
| "Haloperidol is a butyrophenone neuroleptic agent characterized as a high-affinity dopamine antagonist, originally used for the treatment of schizophrenia." | 2.48 | Role of haloperidol in palliative medicine: an update. ( Prommer, E, 2012) |
| "Haloperidol (HP) has been shown to have analgesic & antiemetic properties." | 1.46 | Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department. ( Croft, B; Darracq, MA; Ramirez, R; Stalcup, P, 2017) |
| "Vomiting was controlled in all patients, with the exception of three patients with upper abdomen obstruction who required nasogastric tube placement." | 1.28 | The management of inoperable gastrointestinal obstruction in terminal cancer patients. ( Caraceni, A; De Conno, F; Messina, L; Ripamonti, C; Spoldi, E; Ventafridda, V, 1990) |
| "Severe vomiting was evoked by Apo in dogs, but not by Eph even when lethal dose (20 mg." | 1.28 | [Comparison of central stimulating effects between ephedrine and apomorphine]. ( Li, BH; Li, Q, 1991) |
| "The neuroleptic malignant syndrome is a serious and potentially fatal complication of neuroleptic and other dopamine antagonist drugs that are commonly used in symptom control in advanced cancer." | 1.28 | The neuroleptic malignant syndrome. ( O'Neill, WM, 1990) |
| "Sixty patients with Hodgkin's disease were treated with a polychemotherapy regimen including very emetic dacarbazine and adriamycin in addition to bleomycin and vincristine on 622 treatment days during the last 10 years." | 1.28 | [Management of vomiting induced by polychemotherapy in Hodgkin's disease]. ( Berényi, E; Kiss, E, 1989) |
| "Remoxipride was shown to be a selective dopamine D2 receptor antagonist since it displaced [3H]spiperone (IC50 = 1570 nM) but not [3H]flupentixol (IC50 greater than 100 000 nM) in rat striatum, and did not inhibit striatal DA-sensitive adenylate cyclase in vitro (IC50 greater than 100 000 nM)." | 1.27 | Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. ( Angeby, K; Florvall, L; Hall, H; Köhler, C; Lindbom, LO; Magnusson, O; Ogren, SO, 1984) |
| "Prochlorperazine has an intermediate onset of action and droperidol is the slowest of the three compounds but the only one to provide significant anti-emesis 4-24 hours following administration." | 1.26 | Comparison of droperidol, haloperidol and prochlorperazine as postoperative anti-emetics. ( Bennett, G; Loeser, EA; Machin, R; Stanley, TH, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (48.28) | 18.7374 |
| 1990's | 12 (13.79) | 18.2507 |
| 2000's | 11 (12.64) | 29.6817 |
| 2010's | 15 (17.24) | 24.3611 |
| 2020's | 7 (8.05) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, RC | 1 |
| Bauer, VJ | 1 |
| Kosley, RW | 1 |
| McFadden, AR | 1 |
| Shutske, GM | 1 |
| Cornfeldt, ML | 1 |
| Fielding, S | 1 |
| Geyer, HM | 1 |
| Wilker, JC | 1 |
| Brown, JM | 1 |
| Wilsey, MJ | 1 |
| Dhana, L | 1 |
| Lonsdale, H | 1 |
| Ruberto, AJ | 2 |
| Sivilotti, MLA | 2 |
| Forrester, S | 1 |
| Hall, AK | 2 |
| Crawford, FM | 2 |
| Day, AG | 1 |
| Trajkovski, A | 1 |
| Lang, E | 1 |
| Moussa, G | 1 |
| Genest, M | 1 |
| Villeneuve, E | 1 |
| Wang, JJ | 1 |
| Shahsavari, D | 1 |
| Reznick-Lipina, K | 1 |
| Malik, Z | 1 |
| Weiner, M | 1 |
| Jehangir, A | 1 |
| Repanshek, ZD | 1 |
| Parkman, HP | 1 |
| Rosenthal, J | 1 |
| Howell, M | 1 |
| Earl, V | 1 |
| Malik, M | 1 |
| Ramirez, R | 1 |
| Stalcup, P | 1 |
| Croft, B | 1 |
| Darracq, MA | 1 |
| Roldan, CJ | 1 |
| Chambers, KA | 1 |
| Paniagua, L | 1 |
| Patel, S | 1 |
| Cardenas-Turanzas, M | 1 |
| Chathampally, Y | 1 |
| Dida, J | 1 |
| Walji, N | 1 |
| Smith, TN | 1 |
| Walsh, A | 1 |
| Forest, CP | 1 |
| Dulal, S | 1 |
| Paudel, BD | 1 |
| Neupane, P | 1 |
| Shah, A | 1 |
| Acharya, B | 1 |
| Poudyal, BS | 1 |
| Shilpakar, R | 1 |
| Wood, LA | 1 |
| Hernández-Ramos, I | 1 |
| Parra-Esquivel, P | 1 |
| López-Hernández, Á | 1 |
| Burillo-Putze, G | 1 |
| Hickey, JL | 1 |
| Witsil, JC | 1 |
| Mycyk, MB | 1 |
| McLean, SL | 1 |
| Blenkinsopp, A | 1 |
| Bennett, MI | 1 |
| Kishi, T | 1 |
| Mukai, T | 1 |
| Matsuda, Y | 1 |
| Iwata, N | 1 |
| Silvestris, N | 1 |
| Brunetti, AE | 1 |
| Russano, M | 1 |
| Nardulli, P | 1 |
| Fletcher, DS | 1 |
| Coyne, PJ | 1 |
| Dodson, PW | 1 |
| Parker, GG | 1 |
| Wan, W | 1 |
| Smith, TJ | 1 |
| Murray-Brown, F | 1 |
| Dorman, S | 2 |
| Inayat, F | 1 |
| Virk, HU | 1 |
| Ullah, W | 1 |
| Hussain, Q | 1 |
| Perkins, P | 1 |
| Marchione, P | 1 |
| Vento, C | 1 |
| Marianetti, M | 1 |
| Romeo, T | 1 |
| Amabile, GA | 1 |
| Giacomini, P | 1 |
| Hardy, JR | 1 |
| O'Shea, A | 1 |
| White, C | 2 |
| Gilshenan, K | 1 |
| Welch, L | 1 |
| Douglas, C | 1 |
| Prommer, E | 1 |
| APPIANI, L | 1 |
| CUOCOLO, R | 1 |
| MESSINA, N | 1 |
| CIPRIANI, G | 1 |
| GIORDANO, GB | 1 |
| DYRBERG, V | 1 |
| WEAVER, LC | 1 |
| RAHDERT, E | 1 |
| RICHARDS, AB | 1 |
| ABREU, BE | 1 |
| Vella-Brincat, J | 1 |
| Macleod, AD | 1 |
| Büttner, M | 1 |
| Walder, B | 1 |
| von Elm, E | 1 |
| Tramèr, MR | 1 |
| Krakauer, EL | 1 |
| Zhu, AX | 1 |
| Bounds, BC | 1 |
| Sahani, D | 1 |
| McDonald, KR | 1 |
| Brachtel, EF | 1 |
| Weschules, DJ | 1 |
| McPherson, A | 1 |
| McCann, MA | 1 |
| Sadler, A | 1 |
| Fyvie, J | 1 |
| Bleicher, J | 1 |
| Bhaskara, A | 1 |
| Huyck, T | 1 |
| Constantino, S | 1 |
| Bardia, A | 1 |
| Loprinzi, CL | 1 |
| Silberstein, PT | 1 |
| Usuda, S | 1 |
| Nishikori, K | 1 |
| Noshiro, O | 1 |
| Maeno, H | 1 |
| Schaffer, CB | 1 |
| Shahid, A | 1 |
| Javaid, JI | 1 |
| Davis, JM | 1 |
| Friedlander, ML | 2 |
| Kearsley, JH | 2 |
| Sims, K | 2 |
| Coates, A | 1 |
| Hedley, D | 1 |
| Raghavan, D | 1 |
| Fox, RM | 1 |
| Tattersall, MH | 1 |
| Ogren, SO | 1 |
| Hall, H | 1 |
| Köhler, C | 1 |
| Magnusson, O | 1 |
| Lindbom, LO | 1 |
| Angeby, K | 1 |
| Florvall, L | 1 |
| Grunberg, SM | 1 |
| Gala, KV | 1 |
| Lampenfeld, M | 1 |
| Jamin, D | 1 |
| Johnson, K | 1 |
| Cariffe, P | 1 |
| Strych, D | 1 |
| Krailo, M | 1 |
| Chacón, RD | 1 |
| Bruera, ED | 1 |
| Roca, E | 1 |
| Neidhart, JA | 1 |
| Gagen, M | 1 |
| Young, D | 1 |
| Wilson, HE | 1 |
| Uvnäs-Wallensten, K | 1 |
| Goiny, M | 2 |
| Uvnäs-Moberg, K | 1 |
| Posloncec, B | 1 |
| Blomquist, L | 1 |
| Luthra, YK | 1 |
| Mattsson, JL | 1 |
| Yochmowitz, MG | 1 |
| Keith, JC | 1 |
| Wilson, RC | 1 |
| Booth, NH | 1 |
| Kemppainen, RJ | 1 |
| Davis, LE | 1 |
| Cole, RM | 1 |
| Robinson, F | 1 |
| Harvey, L | 1 |
| Trethowan, K | 1 |
| Murdoch, V | 1 |
| Hudzik, TJ | 2 |
| De Costa, BR | 1 |
| McMillan, DE | 1 |
| Climent, MA | 1 |
| Palau, J | 1 |
| Ruiz, A | 1 |
| Soriano, V | 1 |
| Aznar, E | 1 |
| Olmos, T | 1 |
| Guillem, V | 1 |
| Critchley, P | 1 |
| Plach, N | 1 |
| Grantham, M | 1 |
| Marshall, D | 1 |
| Taniguchi, A | 1 |
| Latimer, E | 1 |
| Jadad, AR | 1 |
| Rabin, BM | 2 |
| Joseph, JA | 2 |
| Hunt, WA | 1 |
| Dalton, TB | 1 |
| Kandasamy, SB | 1 |
| Harris, AH | 1 |
| Ludewigt, B | 1 |
| Erat, S | 1 |
| Hirsch, SR | 1 |
| Kissling, W | 1 |
| Bäuml, J | 1 |
| Power, A | 1 |
| O'Connor, R | 1 |
| Ono, H | 1 |
| Taira, N | 1 |
| Hashimoto, K | 1 |
| Lal, H | 1 |
| Gianutsos, G | 1 |
| Puri, SK | 1 |
| Gylys, JA | 1 |
| Doran, KM | 1 |
| Buyniski, JP | 1 |
| Loeser, EA | 1 |
| Bennett, G | 1 |
| Stanley, TH | 1 |
| Machin, R | 1 |
| Lefebvre, RA | 1 |
| Willems, JL | 1 |
| Kalman, T | 1 |
| Warner, GM | 1 |
| Robbins, EL | 1 |
| Nagel, JD | 1 |
| Barton, MD | 1 |
| Libonati, M | 1 |
| Cohen, PJ | 1 |
| Corsini, GU | 1 |
| Zompo, MD | 1 |
| Cianchetti, C | 1 |
| Mangoni, A | 1 |
| Montastruc, JL | 1 |
| Rascol, O | 1 |
| Montastruc, P | 1 |
| Ventafridda, V | 1 |
| Ripamonti, C | 1 |
| Caraceni, A | 1 |
| Spoldi, E | 1 |
| Messina, L | 1 |
| De Conno, F | 1 |
| Li, Q | 1 |
| Li, BH | 1 |
| Bregni, M | 1 |
| Siena, S | 1 |
| Di Nicola, M | 1 |
| Bonadonna, G | 1 |
| Gianni, AM | 1 |
| Francom, M | 1 |
| O'Neill, WM | 1 |
| Lang, IM | 1 |
| Marvig, J | 1 |
| Backonja, M | 1 |
| Beinlich, B | 1 |
| Dulli, D | 1 |
| Schutta, HS | 1 |
| Berényi, E | 1 |
| Kiss, E | 1 |
| Murakami, M | 1 |
| Ota, K | 1 |
| Silvey, L | 1 |
| Carpenter, JT | 1 |
| Wheeler, RH | 1 |
| Lee, J | 1 |
| Conolley, C | 1 |
| Grob, CS | 1 |
| Saller, R | 1 |
| Hellenbrecht, D | 1 |
| Plotkin, DA | 1 |
| Plotkin, D | 1 |
| Okun, R | 1 |
| Christman, RS | 1 |
| Weinstein, RA | 1 |
| Larose, JB | 1 |
| De Vries, PM | 1 |
| Cole, DR | 1 |
| Duffy, DF | 1 |
| Rotrosen, J | 1 |
| Wallach, MB | 1 |
| Angrist, B | 1 |
| Gershon, S | 1 |
| Wolff, JD | 1 |
| Lionarons, HB | 1 |
| Mesdag, MJ | 1 |
| Niemegeers, CJ | 1 |
| Janssen, PA | 1 |
| Valena, V | 1 |
| Young, WG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Droperidol on Prevention of Emesis From Cannabinoid Hyperemesis Syndrome[NCT05244460] | Phase 3 | 45 participants (Anticipated) | Interventional | 2021-12-02 | Recruiting | ||
| Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial[NCT03056482] | Phase 4 | 33 participants (Actual) | Interventional | 2017-05-21 | Completed | ||
| Haloperidol vs Conventional Therapy for Gastroparesis[NCT02057549] | Phase 4 | 36 participants (Actual) | Interventional | 2012-11-30 | Terminated (stopped due to PI left institution) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The time frame starts from the moment of receiving the study drug to the time when the decision for final disposition is made. Usually after symptoms are controlled, patients are given a PO challenge (food or drink) in order to establish if they are OK to go home. If symptoms return, additional medications are given, the treatment is consider failed and they are admitted to the Hospital.~Patients will not be followed up if admitted to any service. The study ends when final disposition is made.~Patients follow up after final disposition is not part of the study and will not be done." (NCT02057549)
Timeframe: at the time the decision for final disposition is made (about 8 hours)
| Intervention | hours (Median) |
|---|---|
| Haloperidol Plus Conventional Therapy | 4.8 |
| Conventional Therapy | 9 |
(NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Plus Conventional Therapy | 11 |
| Conventional Therapy | 13 |
The Visual Analogue Scale (VAS) ranges from 1-5, with 1 being minimal nausea and 5 being severe nausea. (NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 1.83 |
| Conventional Therapy | 3.39 |
The Visual Analogue Scale (VAS) ranges from 1-5, with 1 being minimal nausea and 5 being severe nausea. (NCT02057549)
Timeframe: before study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 4.53 |
| Conventional Therapy | 4.11 |
(NCT02057549)
Timeframe: 2 hours after study medication given
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Plus Conventional Therapy | 4 |
| Conventional Therapy | 13 |
(NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | Participants (Count of Participants) |
|---|---|
| Haloperidol Plus Conventional Therapy | 11 |
| Conventional Therapy | 5 |
The Visual Analogue Scale (VAS) ranges from 0-10, with 0 being the absence of pain and 10 the worst imaginable pain. (NCT02057549)
Timeframe: 1 hour after study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 3.13 |
| Conventional Therapy | 7.17 |
The Visual Analogue Scale (VAS) ranges from 0-10, with 0 being the absence of pain and 10 the worst imaginable pain. (NCT02057549)
Timeframe: before study medication given
| Intervention | units on a scale (Mean) |
|---|---|
| Haloperidol Plus Conventional Therapy | 8.50 |
| Conventional Therapy | 8.28 |
10 reviews available for haloperidol and Emesis
| Article | Year |
|---|---|
Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting.
Topics: Acute Disease; Antiemetics; Cannabinoids; Haloperidol; Humans; Lorazepam; Nausea; Syndrome; Vomiting | 2019 |
Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts.
Topics: Antiemetics; Antineoplastic Agents; Haloperidol; Humans; Nausea; Ondansetron; Palliative Care; Posto | 2013 |
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review.
Topics: Antipsychotic Agents; Constipation; Double-Blind Method; Drug Therapy, Combination; Granisetron; Hal | 2014 |
Haloperidol for the treatment of nausea and vomiting in palliative care patients.
Topics: Antiemetics; Diphenhydramine; Gels; Haloperidol; Humans; Lorazepam; Nausea; Palliative Care; Randomi | 2015 |
Haloperidol for the treatment of nausea and vomiting in palliative care patients.
Topics: Antiemetics; Haloperidol; Humans; Nausea; Palliative Care; Vomiting | 2009 |
Role of haloperidol in palliative medicine: an update.
Topics: Delirium; Dopamine Antagonists; Haloperidol; Humans; Nausea; Palliative Care; Vomiting | 2012 |
Haloperidol in palliative care.
Topics: Antipsychotic Agents; Conscious Sedation; Delirium; Haloperidol; Humans; Long QT Syndrome; Nausea; V | 2004 |
Is low-dose haloperidol a useful antiemetic?: A meta-analysis of published and unpublished randomized trials.
Topics: Antiemetics; Antineoplastic Agents; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Hal | 2004 |
Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review.
Topics: Antiemetics; Haloperidol; Humans; Nausea; Neoplasms; Palliative Care; Vomiting | 2001 |
[Recent advances in the management of chemotherapy-induced emesis].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Domperidone; Dronabinol; Drug Therapy, | 1986 |
19 trials available for haloperidol and Emesis
| Article | Year |
|---|---|
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Administration, Intravenous; Adult; Antiemetics; Female; Haloperidol; Humans; Male; Marijuana Abuse; | 2021 |
Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis.
Topics: Abdominal Pain; Adult; Analgesics; Antiemetics; Double-Blind Method; Drug Therapy, Combination; Fema | 2017 |
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemo | 2019 |
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptoth | 2013 |
A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antiemetics; Cross-Over Studies; Diphenhydramine; | 2014 |
The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Ha | 2010 |
Is low-dose haloperidol a useful antiemetic?: A meta-analysis of published and unpublished randomized trials.
Topics: Antiemetics; Antineoplastic Agents; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Hal | 2004 |
Impairment of recall improves tolerance of cytotoxic chemotherapy.
Topics: Anti-Anxiety Agents; Antineoplastic Agents; Clinical Trials as Topic; Double-Blind Method; Drug Tole | 1983 |
Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Method; Drug Evaluati | 1984 |
Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide.
Topics: Adult; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Double-Blind Method; Doxorubicin; | 1981 |
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Middle Aged; Nausea; Pip | 2002 |
Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study.
Topics: Age Factors; Aged; Antiemetics; Clinical Trials as Topic; Drug Evaluation; Female; Gastrointestinal | 1975 |
The use of haloperidol for treatment of postoperative nausea and vomiting--a double-blind placebo-controlled trial.
Topics: Abdomen; Adolescent; Adult; Aged; Anesthesia, Inhalation; Anesthetics; Clinical Trials as Topic; Col | 1975 |
Tropisetron plus haloperidol to ameliorate nausea and vomiting associated with high-dose alkylating agent cancer chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Haloperidol; Humans; Indoles; | 1991 |
A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1988 |
[Benefit and risk of high-dose metoclopramide in comparison to high-dose haloperidol or triflupromazine in cisplatin-induced vomiting].
Topics: Cisplatin; Dose-Response Relationship, Drug; Haloperidol; Humans; Metoclopramide; Neoplasms; Risk; T | 1985 |
Low-dose haloperidol as antiemetic treatment in gastrointestinal disorders: a double-blind study.
Topics: Antiemetics; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Gastrointestinal Di | 1974 |
A double-blind cross-over clinical valuation of metoclopramide and a combination of haloperidol and isopropamide iodide in gastroenterology.
Topics: Adolescent; Adult; Antiemetics; Clinical Trials as Topic; Colonic Diseases; Constipation; Crohn Dise | 1969 |
Haloperidol for radiation sickness: Control of associated nausea, vomiting, and anorexia.
Topics: Adult; Aged; Clinical Trials as Topic; Feeding and Eating Disorders; Female; Haloperidol; Humans; Ma | 1974 |
59 other studies available for haloperidol and Emesis
| Article | Year |
|---|---|
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 4. Central nervous system depressants.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Avoidance Learning; Central Nervous System | 1978 |
Acute Treatment of Adolescent Cannabinoid Hyperemesis Syndrome With Haloperidol, Lorazepam, and/or Capsaicin: A Single Institution Case Series.
Topics: Adolescent; Adult; Cannabinoids; Capsaicin; Child; Haloperidol; Humans; Lorazepam; Nausea; Syndrome; | 2023 |
Haloperidol as an anti-emetic for Cannabis Hyperemesis Syndrome in the ED.
Topics: Antiemetics; Cannabis; Haloperidol; Humans; Nausea; Vomiting | 2021 |
Topics: Cannabis; Haloperidol; Humans; Ondansetron; Syndrome; Vomiting | 2021 |
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Topics: Antiemetics; Cannabis; Female; Haloperidol; Humans; Hyperemesis Gravidarum; Ondansetron; Pregnancy; | 2021 |
Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain.
Topics: Abdominal Pain; Adult; Antiemetics; Diabetes Mellitus; Emergency Service, Hospital; Female; Florida; | 2021 |
Cannabinoid Hyperemesis Syndrome Secondary to Delta-8 THC Use.
Topics: Administration, Cutaneous; Adult; Antiemetics; Cannabinoid Receptor Agonists; Capsaicin; Dopamine An | 2021 |
Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department.
Topics: Abdominal Pain; Adult; Antiemetics; California; Diabetes Mellitus, Type 1; Emergency Service, Hospit | 2017 |
BET 1: Haloperidol in cannabinoid hyperemesis syndrome.
Topics: Adult; Antiemetics; Cannabinoids; Haloperidol; Humans; Male; Vomiting | 2018 |
[Spontaneuos pneumomediastinum secondary to cannabinoid hyperemesis syndrome].
Topics: Antiemetics; Cannabinoids; Capsaicin; Haloperidol; Humans; Male; Marijuana Abuse; Mediastinal Emphys | 2019 |
Haloperidol for treatment of cannabinoid hyperemesis syndrome.
Topics: Abdominal Pain; Adult; Antiemetics; Cannabinoids; Haloperidol; Humans; Male; Marijuana Abuse; Nausea | 2013 |
Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?
Topics: Adult; Antiemetics; Cannabinoids; Haloperidol; Humans; Male; Marijuana Abuse; Nausea; Syndrome; Trea | 2017 |
Hemiballismus in subthalamic haemorrhage: efficacy of levetiracetam.
Topics: Aged; Anti-Dyskinesia Agents; Anticonvulsants; Antihypertensive Agents; Ataxia; Cerebellum; Dose-Res | 2009 |
[R 1625 in the treatment of postoperative vomiting].
Topics: Anesthesia; Haloperidol; Humans; Hypnotics and Sedatives; Postoperative Nausea and Vomiting; Vomitin | 1961 |
[R-1625 in the prevention and therapy of vomiting in surgery].
Topics: Antiemetics; Biomedical Research; Haloperidol; Surgical Procedures, Operative; Vomiting | 1961 |
[1st observations on the preventive action of haloperidol in vomiting in gaseous encephalography].
Topics: Anesthesia; Haloperidol; Hypnotics and Sedatives; Pneumoencephalography; Vectorcardiography; Vomitin | 1961 |
Haloperidol (Serenase) in the prevention of postoperative nausea and vomiting.
Topics: Anesthesia; Haloperidol; Humans; Hypnotics and Sedatives; Nausea; Postoperative Nausea and Vomiting; | 1962 |
EFFECT OF ANTIEMETICS AND OTHER COMPOUNDS ON PROTOVERATRINE INDUCED EMESIS IN DOGS.
Topics: Antiemetics; Atropine; Benzamides; Dogs; Haloperidol; Meclizine; Niacin; Perphenazine; Pharmacology; | 1964 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2005. A 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Antiemetics; Antineoplastic Agents, Hormonal; Barrett Esop | 2005 |
Tolerability of the compound ABHR in hospice patients.
Topics: Aged; Antiemetics; Cohort Studies; Diphenhydramine; Drug Combinations; Female; Haloperidol; Hospice | 2005 |
Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic.
Topics: Aged; Antiemetics; Dopamine Antagonists; Female; Haloperidol; Humans; Nausea; Parkinsonian Disorders | 2006 |
Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.
Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clini | 2008 |
Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity.
Topics: Animals; Antipsychotic Agents; Apomorphine; Benzamides; Chlorpropamide; Dogs; Drug Evaluation, Precl | 1981 |
A case report of vomiting related to the interactions of antipsychotics and benztropine.
Topics: Adolescent; Antipsychotic Agents; Benztropine; Drug Interactions; Fluphenazine; Haloperidol; Humans; | 1981 |
Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy.
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Drug Therapy, Combination; Female; Haloperi | 1983 |
Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Benzamides; Binding | 1984 |
[Emesis due to cytostatic drugs. Update and review of our experiences].
Topics: Antineoplastic Agents; Dexamethasone; Haloperidol; Humans; Metoclopramide; Prochlorperazine; Vomitin | 1983 |
Effect of apomorphine on peripheral venous gastrin and insulin levels in conscious dogs.
Topics: Animals; Apomorphine; Dogs; Dose-Response Relationship, Drug; Female; Gastrins; Haloperidol; Insulin | 1981 |
Increased levels of VIP (vasoactive intestinal polypeptide)-like immunoreactivity in peripheral venous blood of dogs following injections of apomorphine and bromocriptine. Do dopaminergic agents induce gastric relaxation and hypotension by a release of en
Topics: Animals; Apomorphine; Bromocriptine; Dogs; Gastrointestinal Hormones; Gastrointestinal Motility; Hal | 1982 |
Inhibition of radioemesis by disruption of catecholamines in dogs.
Topics: Animals; Catecholamines; Dogs; Haloperidol; Hydroxydopamines; Male; Methyltyrosines; Neurons; Probab | 1981 |
Failure of naloxone to prevent the emetic activity of apomorphine in dogs.
Topics: Animals; Apomorphine; Dogs; Droperidol; Female; Fentanyl; Haloperidol; Injections, Intravenous; Male | 1981 |
Pharmacologic control of vomiting.
Topics: Animals; Antiemetics; Benzamides; Cats; Dogs; Haloperidol; Motion Sickness; Phenothiazines; Swine; V | 1980 |
Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.
Topics: Analgesics; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Haloperidol; Humans | 1994 |
Sigma receptor-mediated emetic response in pigeons: agonists, antagonists and modifiers.
Topics: Animals; Anti-Anxiety Agents; Antiemetics; Binding Sites; Columbidae; Drug Interactions; Emetics; Gu | 1993 |
The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; | 1998 |
Behavioral endpoints for radiation injury.
Topics: Amphetamine; Animals; Argon; Avoidance Learning; Behavior, Animal; Central Nervous System Stimulants | 1994 |
Effects of exposure to different types of radiation on behaviors mediated by peripheral or central systems.
Topics: Amphetamine; Animals; Avoidance Learning; Behavior, Animal; Cobalt Radioisotopes; Dopamine Agents; D | 1998 |
Behavioural and vegetative effects of dibutyryl cyclic AMP on conscious dogs.
Topics: Animals; Atropine; Behavior, Animal; Bucladesine; Butyrates; Cyclic AMP; Diarrhea; Dogs; Dose-Respon | 1976 |
A comparison of narcotic analgesics with neuroleptics on behavioral measures of dopaminergic activity.
Topics: Aggression; Amphetamine; Analgesics, Opioid; Animals; Apomorphine; Behavior, Animal; Brain; Cataleps | 1975 |
Antagonism of cisplatin induced emesis in the dog.
Topics: Animals; Antiemetics; Chlorpromazine; Cisplatin; Dogs; Dronabinol; Female; Haloperidol; Indoles; Mal | 1979 |
Comparison of droperidol, haloperidol and prochlorperazine as postoperative anti-emetics.
Topics: Droperidol; Haloperidol; Humans; Postoperative Complications; Prochlorperazine; Sodium Chloride; Vom | 1979 |
Gastric relaxation by morphine, apomorphine and fentanyl in the conscious dog.
Topics: Animals; Apomorphine; Benzimidazoles; Dogs; Domperidone; Fentanyl; Haloperidol; Morphine; Muscle Con | 1979 |
Protracted vomiting following abrupt cessation of psychotropics: a case report.
Topics: Adult; Benztropine; Depression; Drug Therapy, Combination; Haloperidol; Humans; Imipramine; Male; Sc | 1978 |
Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in Parkinsonism.
Topics: Adult; Apomorphine; Drug Therapy, Combination; Haloperidol; Humans; Male; Metoclopramide; Parkinson | 1976 |
Sigma ligand-induced emesis in the pigeon.
Topics: Animals; Apomorphine; Columbidae; Dextromethorphan; Dizocilpine Maleate; Dopamine Agents; Guanidines | 1992 |
Naloxone or haloperidol but not yohimbine reverse apomorphine-induced respiratory depression.
Topics: Animals; Apomorphine; Dogs; Drug Interactions; Female; Haloperidol; Injections, Intravenous; Male; N | 1992 |
The management of inoperable gastrointestinal obstruction in terminal cancer patients.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Butylscopolammonium Bromide; Drug Administratio | 1990 |
[Comparison of central stimulating effects between ephedrine and apomorphine].
Topics: Animals; Apomorphine; Blepharoptosis; Catalepsy; Ephedrine; Haloperidol; Male; Mice; Motor Activity; | 1991 |
Compounding nausea aid.
Topics: Benztropine; Chemistry, Pharmaceutical; Dexamethasone; Diphenhydramine; Drug Combinations; Drug Comp | 1991 |
The neuroleptic malignant syndrome.
Topics: Adult; Female; Haloperidol; Humans; Metoclopramide; Neuroleptic Malignant Syndrome; Postoperative Co | 1990 |
Functional localization of specific receptors mediating gastrointestinal motor correlates of vomiting.
Topics: Animals; Apomorphine; Atropine; Copper; Copper Sulfate; Digestive System; Dogs; Domperidone; Female; | 1989 |
Haloperidol and lorazepam for the treatment of nausea and vomiting associated with the treatment of intractable migraine headaches.
Topics: Adult; Dihydroergotamine; Female; Haloperidol; Humans; Lorazepam; Migraine Disorders; Nausea; Vomiti | 1989 |
[Management of vomiting induced by polychemotherapy in Hodgkin's disease].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Halop | 1989 |
Persistent supersensitivity vomiting following neuroleptic withdrawal in an adolescent.
Topics: Adolescent; Haloperidol; Humans; Male; Substance Withdrawal Syndrome; Vomiting | 1986 |
Haloperidol in the treatment of nausea and vomiting due to cytotoxic drug administration.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Female; Haloperidol; Humans; Male; Middle Aged; N | 1973 |
Antagonism of apomorphine-induced sterotypy and emesis in dogs by thioridazine, haloperidol, and pimozide.
Topics: Animals; Apomorphine; Behavior, Animal; Blood-Brain Barrier; Chemoreceptor Cells; Corpus Striatum; D | 1972 |
The effect of haloperidol with promethazine on postoperative vomiting.
Topics: Anesthesia, General; Atropine; Haloperidol; Humans; Nausea; Promethazine; Vomiting | 1970 |
A comparative study of the inhibitory effects of haloperidol and trifluperidol on learned shock-avoidance behavioural habits and on apomorphine-induced emesis in mongrel dogs and in beagles.
Topics: Animals; Antidepressive Agents; Apomorphine; Avoidance Learning; Behavior, Animal; Dogs; Haloperidol | 1965 |
Dental erosion patterns from intrinsic acid regurgitation and vomiting.
Topics: Adult; Aged; Bicuspid; Bulimia; Case-Control Studies; Chi-Square Distribution; Chronic Disease; Cusp | 2002 |